756869-43-9

Basic information

• Product Name: [4-(4-allyloxy-phenoxy)-benzyl]-(2-methyl-3-nitro-phenyl)-amine
• Synonyms: [4-(4-allyloxy-phenoxy)-benzyl]-(2-methyl-3-nitro-phenyl)-amine
• CAS NO: 756869-43-9
• Molecular Weight: 390.439
• Mol File: 756869-43-9.mol

Chemical Properties

• CAS DataBase Reference: [4-(4-allyloxy-phenoxy)-benzyl]-(2-methyl-3-nitro-phenyl)-amine(CAS DataBase Reference)
• NIST Chemistry Reference: [4-(4-allyloxy-phenoxy)-benzyl]-(2-methyl-3-nitro-phenyl)-amine(756869-43-9)
• EPA Substance Registry System: [4-(4-allyloxy-phenoxy)-benzyl]-(2-methyl-3-nitro-phenyl)-amine(756869-43-9)

Safety Data

• Hazardous Substances Data: 756869-43-9(Hazardous Substances Data)

Upstream product

• 603-83-8 3-nitro-o-tolylamine 
• 448956-60-3 4-[4-(allyloxy)phenoxy]benzaldehyde 
• 123-31-9 hydroquinone 
• 157259-26-2 4-(allyloxy)phenyl-4-methylbenzenesulfonate 
• 459-57-4 4-fluorobenzaldehyde 
• 6411-34-3 4-allyloxyphenol 

Downstream Products

• 756869-51-9 tert-butyl 6-O-(4-{4-[(benzyl{2-methyl-3-[(methylsulfonyl)amino]phenyl}amino)methyl]phenoxy}phenyl)-2,4-dideoxy-3,5-O-(1-methylethylidene)-D-erythro-hexonate 
• 756869-53-1 (3R,5S)-6-[4-(4-{[Benzyl-(3-methanesulfonylamino-2-methyl-phenyl)-amino]-methyl}-phenoxy)-phenoxy]-3,5-dihydroxy-hexanoic acid tert-butyl ester 
• 448956-58-9 tert-butyl 6-O-[4-(4-{[benzyl(2-methyl-3-nitrophenyl)amino]methyl}phenoxy)phenyl]-2,4-dideoxy-3,5-O-(1-methylethylidene)-D-erythro-hexonate 
• 448956-61-4 4-(4-{[benzyl-(2-methyl-3-nitro-phenyl)-amino]-methyl}-phenoxy)-phenol 
• 756869-45-1 [4-(4-allyloxy-phenoxy)-benzyl]-benzyl-(2-methyl-3-nitro-phenyl)-amine 

Relevant articles and documents

Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators

Much has been learned about the consequences of glucocorticoid receptor antagonism by studying steroidal active antagonists such as RU-38486 (1). In the liver glucocorticoid receptor antagonism suppresses hepatic glucose production decreasing plasma glucose levels; however, extrahepatic antagonism produces several undesirable side effects including activation of the hypothalamic pituitary adrenal axis. A series of nonsteroidal passive N-(3-dibenzylamino-2- alkyl-phenyl)-methanesulfonamide glucocorticoid receptor modulators was discovered. Liver selective and systemically available members of this series were found and characterized in diabetes and side effect rodent models. A highly liver selective member of this series, acid 14, shows efficacy in the ob/ob model of diabetes. It lowers plasma glucose, cholesterol, and free fatty acid concentrations and reduces the rate of body weight gain. The structurally related systemically available passive modulator 12 lowers glucose, HbA 1c, triglyceride, free fatty acid, and cholesterol levels. Interestingly, it did not acutely activate the hypothalamic pituitary adrenal axis in unstressed CD-1 mice or have the abortive effects observed with 1. These results indicate that passive GR antagonists may have utility as antidiabetic agents.

Synthesis, activity, metabolic stability, and pharmacokinetics of glucocorticoid receptor modulator-statin hybrids

The synthesis, activity, metabolic stability, and pharmacokinetics of steroidal and nonsteroidal glucocorticoid receptor modulator-statin hybrids is reported. Potent steroidal antagonist-statin hybrids like 22 (h-GR binding IC50=7nM) and nonsteroidal modulator hybrids like 16 (h-GR binding IC50=2nM) were discovered. Appending a 'statin'-like diol-acid group to the modulators dramatically improved metabolic stability (and in some cases hepatocyte activity), but did not impart hepatoselectivity.